{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:28:36Z","timestamp":1787041716821,"version":"build-2736575974"},"reference-count":413,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:00:00Z","timestamp":1780704000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119009","type":"journal-article","created":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T23:07:25Z","timestamp":1780787245000},"page":"119009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956\u20132025)"],"prefix":"10.1016","volume":"317","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6678-8505","authenticated-orcid":false,"given":"Mateusz D.","family":"Tomczyk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Wawrzynosek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daria","family":"Gendosz de Carrillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Krzystanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pan","family":"Pantziarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halina","family":"J\u0119drzejowska-Szypu\u0142ka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119009_bib1","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119009_bib2","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug repurposing: a promising tool to accelerate the drug discovery process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119009_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib4","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3332\/ecancer.2014.485","article-title":"The repurposing drugs in oncology (ReDO) project","volume":"8","author":"Pantziarka","year":"2014","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.ejmech.2026.119009_bib5","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2217\/fon.14.244","article-title":"Repurposing drugs in your medicine cabinet: untapped opportunities for cancer therapy?","volume":"11","author":"Pantziarka","year":"2015","journal-title":"Future Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib14","author":"V\u00f6gtli"},{"issue":"95","key":"10.1016\/j.ejmech.2026.119009_bib15","first-page":"23407","article-title":"Withdrawal of approval of 92 new drug applications and 49 abbreviated new drug applications","volume":"74","year":"2009","journal-title":"Fed. Regist."},{"issue":"178","key":"10.1016\/j.ejmech.2026.119009_bib18","first-page":"43388","article-title":"Determination that CORTONE (cortisone acetate) tablets and other drug products were not withdrawn from sale for reasons of safety or effectiveness","volume":"82","year":"2017","journal-title":"Fed. Regist."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119009_bib19","first-page":"25","article-title":"Memories of Mannheim","volume":"7","author":"Pizzi","year":"2004","journal-title":"Mod. Drug Discov."},{"issue":"6","key":"10.1016\/j.ejmech.2026.119009_bib20","doi-asserted-by":"crossref","first-page":"926","DOI":"10.18203\/2319-2003.ijbcp20253293","article-title":"Assessment of antidiabetic drug utilization and prescribing trends in outpatient care at a district general hospital in central Maharashtra","volume":"14","author":"Kothari","year":"2025","journal-title":"Int. J. Basic Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fcdhc.2022.934629","article-title":"BrazIliaN Type 1 & 2 DiabetEs Disease Registry (BINDER): longitudinal, real-world study of diabetes mellitus control in Brazil","volume":"3","author":"de Almeida-Pititto","year":"2022","journal-title":"Front. Clin. Diabetes Healthc."},{"key":"10.1016\/j.ejmech.2026.119009_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2020-001279","article-title":"Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012\u20132018","volume":"8","author":"Engler","year":"2020","journal-title":"BMJ Open Diabetes Res. Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2024.111781","article-title":"Profiles of sulfonylurea use in type 2 diabetes mellitus: an analysis of clinical practice over the last 10 years","volume":"214","author":"Baccetti","year":"2024","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib24","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1248\/bpb.b22-00710","article-title":"Prescription trends for the antidiabetic agents used to treat type 2 diabetes mellitus in Japan from 2012\u20132020: a time-series analysis","volume":"46","author":"Iketani","year":"2023","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejmech.2026.119009_bib25","article-title":"Trends of antidiabetic drug use in adult type 2 diabetes in Korea in 2002\u20132013: a nationwide population-based cohort study","volume":"95","author":"Ko","year":"2016","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejmech.2026.119009_bib26","series-title":"Trends in the Pharmaceutical Treatment Of Diabetes, 1997 to 2007, Research Findings No. 30","author":"Sarpong","year":"2010"},{"issue":"6","key":"10.1016\/j.ejmech.2026.119009_bib27","doi-asserted-by":"crossref","DOI":"10.1111\/1753-0407.70108","article-title":"Trends in pharmacological treatment of patients with new onset type 2 diabetes: usage patterns in an evolving guideline landscape","volume":"17","author":"Hou","year":"2025","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib28","first-page":"2009","article-title":"Trends in use of sulfonylurea types among US adults with diabetes: NHANES 1999\u20132020","volume":"38","author":"Shin","year":"2023","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib29","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.2337\/diacare.26.6.1852","article-title":"Rapid increase in the use of oral antidiabetic drugs in the United States, 1990\u20132001","volume":"26","author":"Wysowski","year":"2003","journal-title":"Diabetes Care"},{"issue":"10","key":"10.1016\/j.ejmech.2026.119009_bib30","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1634\/theoncologist.2013-0177","article-title":"Effects of sulfonylureas on tumor growth: a review of the literature","volume":"18","author":"Pasello","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2026.119009_bib31","first-page":"121","article-title":"Therapeutic aspects of sulfonylureas: a brief review","volume":"8","author":"Sen","year":"2016","journal-title":"J. Chem. Pharmaceut. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib32","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1080\/13543784.2017.1333104","article-title":"Enemies or weapons in hand: investigational anti-diabetic drug glibenclamide and cancer risk","volume":"26","author":"Gao","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"key":"10.1016\/j.ejmech.2026.119009_bib33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/cbdd.13013","article-title":"New insights into antidiabetic drugs: possible applications in cancer treatment","volume":"90","author":"Shafiei-Irannejad","year":"2017","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.119009_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2019.172598","article-title":"Sulfonylurea derivatives and cancer, friend or foe?","volume":"861","author":"Hendriks","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib35","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1634\/theoncologist.2011-0462","article-title":"Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis","volume":"17","author":"Soranna","year":"2012","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ejmech.2026.119009_bib36","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.metabol.2013.01.014","article-title":"Metformin and sulfonylureas in relation to cancer risk in type II diabetes patients: a meta-analysis using primary data of published studies","volume":"62","author":"Thakkar","year":"2013","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.119009_bib37","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","article-title":"Mortality risk among sulfonylureas: a systematic review and network meta-analysis","volume":"3","author":"Simpson","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119009_bib38","article-title":"Pharmacologic therapy of diabetes and overall cancer risk and mortality: a meta-analysis of 265 studies","volume":"5","author":"Wu","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib39","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s12253-018-0402-z","article-title":"Anti-diabetic drugs: cure or risk factors for cancer?","volume":"24","author":"Laskar","year":"2018","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib40","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/7676909","article-title":"Monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients: a systematic review and meta-analysis","volume":"2019","author":"Mekuria","year":"2019","journal-title":"J. Diabetes Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib41","first-page":"185","article-title":"Toxicology of sulfonylureas","volume":"119","author":"Hartig","year":"1996"},{"key":"10.1016\/j.ejmech.2026.119009_bib42","first-page":"73","article-title":"Sulfonylureas: physico-chemical properties, analytical methods of determination and bioavailability","volume":"119","author":"Ali","year":"1996"},{"key":"10.1016\/j.ejmech.2026.119009_bib43","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/1615-1003(200205)31:3<252::AID-PAUZ252>3.0.CO;2-P","article-title":"Sulfonylharnstoffe und Glinide: vom Chemotherapeutikum zum Antidiabetikum","volume":"31","author":"Mark","year":"2002","journal-title":"Pharm. Unserer Zeit"},{"key":"10.1016\/j.ejmech.2026.119009_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1568026620666191224141617","article-title":"Mechanisms and characteristics of sulfonylureas and glinides","volume":"20","author":"Lv","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib45","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3390\/ijms26041429","article-title":"Combining sulfonylureas with anticancer drugs: evidence of synergistic efficacy with doxorubicin in vitro and in vivo","volume":"26","author":"Tomczyk","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1345\/aph.1C397","article-title":"Glimepiride pharmacokinetics in obese versus non-obese diabetic patients","volume":"38","author":"Shukla","year":"2004","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119009_bib48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1002\/ddr.21640","article-title":"Selected pharmacotherapy agents as antiproliferative and anti-inflammatory compounds","volume":"81","author":"AlKhalil","year":"2020","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib49","first-page":"52","article-title":"An in-vitro and in silico anticancer study of FDA approved antidiabetic drugs glimepiride and empagliflozin: life sciences-biochemistry for better diagnosis and therapy","volume":"10","author":"Faridi","year":"2022","journal-title":"Int. J. Life Sci. Pharma Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.117162","article-title":"Glimepiride overcomes acquired resistance to EGFR TKIs in lung cancer via the AMPK\/ERK\/MMP7 signaling pathway","volume":"241","author":"Zhang","year":"2025","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib51","doi-asserted-by":"crossref","DOI":"10.1111\/cbdd.14403","article-title":"Discovery of small molecule c-Maf inhibitors using molecular docking-based virtual screening, molecular dynamics simulation, and biological evaluation","volume":"103","author":"Hu","year":"2024","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ejmech.2026.119009_bib52","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/s13046-021-02077-4","article-title":"Downregulated CLIP3 induces radioresistance by enhancing stemness and glycolytic flux in glioblastoma","volume":"40","author":"Kang","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ejmech.2026.119009_bib53","first-page":"247","article-title":"Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus","volume":"47","author":"von Nicolai","year":"1997","journal-title":"Arzneimittelforschung"},{"key":"10.1016\/j.ejmech.2026.119009_bib55","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1046\/j.1365-2125.2000.00162.x","article-title":"Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes","volume":"49","author":"Davis","year":"2000","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib56","first-page":"27","article-title":"A quantitative structure\u2013toxicity relationship of drugs on rat","volume":"40","author":"Separham","year":"2011","journal-title":"Rev. Colomb. Cienc. Qu\u00edm. Farm."},{"key":"10.1016\/j.ejmech.2026.119009_bib57","first-page":"9099","article-title":"Protective effects of gliclazide on high glucose and AGEs-induced damage of glomerular mesangial cells and renal tubular epithelial cells via inhibiting RAGE-p22phox-NF-kB pathway","volume":"23","author":"Yang","year":"2019","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119009_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.0954-6820.1980.tb01199.x","article-title":"Comparative single-dose kinetics and effects of four sulfonylureas in healthy volunteers","volume":"208","author":"Sartor","year":"1980","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.ejmech.2026.119009_bib59","series-title":"Micronase (Glyburide): Pharmacological and Clinical Evaluation","first-page":"5","article-title":"Toxicologic studies of glyburide","volume":"vol. 382","author":"Webster","year":"1975"},{"key":"10.1016\/j.ejmech.2026.119009_bib60","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jpba.2018.03.025","article-title":"Unveiling anticancer potential of glibenclamide: its synergistic cytotoxicity with doxorubicin on cancer cells","volume":"154","author":"Subramaniyam","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119009_bib61","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/sj.bjp.0703863","article-title":"The sulphonylurea glibenclamide inhibits multidrug resistance protein (MRP1) activity in human lung cancer cells","volume":"132","author":"Payen","year":"2001","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119009_bib62","doi-asserted-by":"crossref","first-page":"991","DOI":"10.18388\/abp.1999_4124","article-title":"The access of metabolites into yeast mitochondria in the presence and absence of the voltage dependent anion selective channel (YVDAC1)","volume":"46","author":"Kmita","year":"1999","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.ejmech.2026.119009_bib63","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s002329900332","article-title":"Membrane potassium channels and human bladder tumor cells: II. Growth properties","volume":"161","author":"Wondergem","year":"1998","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.ejmech.2026.119009_bib64","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/jcp.1041620202","article-title":"Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture","volume":"162","author":"Woodfork","year":"1995","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib65","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1756-9966-32-32","article-title":"Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer","volume":"32","author":"Rong","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib66","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/2050-6511-14-6","article-title":"Glibenclamide inhibits cell growth by inducing G0\/G1 arrest in the human breast cancer cell line MDA-MB-231","volume":"14","author":"N\u00fa\u00f1ez","year":"2013","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib67","author":"Glipizide"},{"key":"10.1016\/j.ejmech.2026.119009_bib68","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1002\/cpt1972135part1710","article-title":"Pharmacokinetics and biotransformation of chlorpropamide in man","volume":"13","author":"Taylor","year":"1972","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib69","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1021\/cg050049m","article-title":"Amphiphilic block copolymer as a crystal habit modifier","volume":"5","author":"Kuldipkumar","year":"2005","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejmech.2026.119009_bib71","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1002\/jps.2600711119","article-title":"Bioavailability of tolazamide from tablets: comparison of in vitro and in vivo results","volume":"71","author":"Welling","year":"1982","journal-title":"J. Pharmacol. Sci."},{"issue":"15","key":"10.1016\/j.ejmech.2026.119009_bib72","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1001\/jama.1956.02960500015005","article-title":"Clinical experiences with carbutamide, an orally given hypoglycemic agent: preliminary report","volume":"160","author":"Ridolfo","year":"1956","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.119009_bib73","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2337\/diab.6.1.2","article-title":"Toxicological studies on carbutamide","volume":"6","author":"Anderson","year":"1957","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib74","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1055\/s-0028-1116221","article-title":"Ein neues antidiabetisches Prinzip. Ergebnisse klinischer Untersuchungen","volume":"80","author":"Franke","year":"1955","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.ejmech.2026.119009_bib75","first-page":"444","article-title":"Sulfanilyl- und sulfonylcarbamins\u00e4ure-Derivate und ihre blutzuckersenkende Wirkung [Sulfanilyl- and sulfonylcarbamic acid derivatives and their hypoglycemic effects]","volume":"8","author":"Haack","year":"1958","journal-title":"Arzneim.-Forsch."},{"key":"10.1016\/j.ejmech.2026.119009_bib76","first-page":"102","article-title":"Clinical use of oral sulfonylurea compounds in diabetes mellitus","volume":"31","author":"Colwell","year":"1957","journal-title":"Q. Bull. Northwest. Univ. Med. Sch."},{"key":"10.1016\/j.ejmech.2026.119009_bib77","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/BF00259916","article-title":"Die Wirkung von N-sulfanilyl-N-butylcarbamid auf Stoffwechsel und Wachstum von Transplantationstumoren","volume":"232","author":"Kunz","year":"1957","journal-title":"Naunyn-Schmiedebergs Arch. Exp. Pathol. Pharmakol."},{"key":"10.1016\/j.ejmech.2026.119009_bib78","first-page":"460","article-title":"Sur l\u2019action t\u00e9ratog\u00e8ne de l\u2019aminoph\u00e9nurobutane BZ chez la ratte","volume":"246","author":"Tuchmann-Duplessis","year":"1958","journal-title":"C. R. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib79","first-page":"167","article-title":"A propos de l\u2019action t\u00e9ratog\u00e8ne d\u2019un sulfamide hypoglyc\u00e9miant (N-sulfanilil-N-butylur\u00e9e-BZ55)","volume":"19","author":"De Meyer","year":"1958","journal-title":"Ann. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119009_bib80","first-page":"156","article-title":"Influence d\u2019un sulfamide hypoglyc\u00e9miant, l\u2019aminoph\u00e9nurobutane BZ 55, sur la gestation de la ratte","volume":"246","author":"Tuchmann-Duplessis","year":"1958","journal-title":"C. R. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib81","first-page":"1133","article-title":"Sur l\u2019action abortive et t\u00e9ratog\u00e8ne de la 6-chloropurine","volume":"153","author":"Tuchmann-Duplessis","year":"1959","journal-title":"C. R. Soc. Biol. (Paris)"},{"key":"10.1016\/j.ejmech.2026.119009_bib82","first-page":"1193","article-title":"Production de malformations chez la souris et le lapin par administration d\u2019un sulfamide hypoglyc\u00e9miant, la carbutamide","volume":"158","author":"Tuchmann-Duplessis","year":"1963","journal-title":"C. R. Soc. Biol. (Paris)"},{"key":"10.1016\/j.ejmech.2026.119009_bib83","first-page":"956","article-title":"Photoallergie durch Nadisan (Carbutamid), Schweiz","volume":"87","author":"Burckhardt","year":"1957","journal-title":"Med. Wochenschr."},{"key":"10.1016\/j.ejmech.2026.119009_bib84","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1002\/ardp.19843171103","article-title":"Photochemische Modell-Studien an lichtdermatoseninduzierenden Pharmaka: sulfonamide und sulfonylharnstoffe","volume":"317","author":"Golpashin","year":"1984","journal-title":"Arch. Pharm. (Weinh.)"},{"key":"10.1016\/j.ejmech.2026.119009_bib85","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1007\/BF03259864","article-title":"Adverse cardiovascular effects of sulphonylurea drugs: clinical significance","volume":"2","author":"Huupponen","year":"1987","journal-title":"Med. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib86","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0531-5131(02)01278-5","article-title":"Sulfonylureas in the prevention of vascular complications: from UKPDS to the ADVANCE study","volume":"1253","author":"Krentz","year":"2003","journal-title":"Int. Congr. Ser."},{"key":"10.1016\/j.ejmech.2026.119009_bib87","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/1523-1747.ep12257972","article-title":"Tissue culture techniques in the study of cell photobiology and phototoxicity","volume":"54","author":"Freeman","year":"1970","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119009_bib88","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/diab.26.2.156","article-title":"Tolbutamide-induced hemolytic anemia","volume":"26","author":"Malacarne","year":"1977","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib89","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1021\/jm00171a013","article-title":"Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships","volume":"33","author":"Howbert","year":"1990","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib90","doi-asserted-by":"crossref","first-page":"33501","DOI":"10.1074\/jbc.273.50.33501","article-title":"Glucose and tolbutamide induce apoptosis in pancreatic beta-cells: a process dependent on intracellular Ca2+ concentration","volume":"273","author":"Efanova","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib91","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1016\/j.bcp.2004.01.016","article-title":"Beta-cell toxicity of ATP-sensitive K+ channel-blocking insulin secretagogues","volume":"67","author":"Rustenbeck","year":"2004","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib92","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0014-5793(98)00390-1","article-title":"The K-ATP channel regulates the effect of Ca2+ on gap junction permeability in cultured astrocytes","volume":"427","author":"Granda","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.119009_bib93","doi-asserted-by":"crossref","first-page":"8387","DOI":"10.1073\/pnas.95.14.8387","article-title":"Human \u03b1-endosulfine, a possible regulator of sulfonylurea-sensitive KATP channel: molecular cloning, expression and biological properties","volume":"95","author":"H\u00e9ron","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2026.119009_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1469-7793.1997.00035.x","article-title":"The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation","volume":"504","author":"Gribble","year":"1997","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib95","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/0028-3908(93)90059-C","article-title":"Characterization and solubilization of the sulphonylurea receptor in rat brain","volume":"32","author":"Niki","year":"1993","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.119009_bib96","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1046\/j.1471-4159.2000.741249.x","article-title":"ATP-sensitive potassium channel regulates astrocytic gap junction permeability by a Ca2+-independent mechanism","volume":"74","author":"Velasco","year":"2000","journal-title":"J. Neurochem."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119009_bib97","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S0014-5793(01)03181-7","article-title":"Proliferation of C6 glioma cells is blunted by the increase in gap junction communication caused by tolbutamide","volume":"509","author":"S\u00e1nchez-Alvarez","year":"2001","journal-title":"FEBS Lett."},{"issue":"2","key":"10.1016\/j.ejmech.2026.119009_bib98","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/glia.20363","article-title":"Tolbutamide reduces glioma cell proliferation by increasing connexin43, which promotes the up-regulation of p21 and p27 and subsequent changes in retinoblastoma phosphorylation","volume":"54","author":"S\u00e1nchez-Alvarez","year":"2006","journal-title":"Glia"},{"issue":"2","key":"10.1016\/j.ejmech.2026.119009_bib99","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1083\/jcb.201404136","article-title":"Targeting potassium channels in cancer","volume":"206","author":"Huang","year":"2014","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119009_bib100","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejphar.2005.10.008","article-title":"Inhibition of 1-methyl-4-phenylpyridinium-induced mitochondrial dysfunction and cell death in PC12 cells by sulfonylurea glibenclamide","volume":"527","author":"Lee","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib101","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0925-4439(98)00083-0","article-title":"The parkinsonian neurotoxin MPP+ opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism","volume":"1453","author":"Cassarino","year":"1999","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2026.119009_bib102","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1074\/jbc.M310711200","article-title":"Molecular modeling correctly predicts the functional importance of Phe594 in transmembrane helix 11 of the multidrug resistance protein, MRP1 (ABCC1)","volume":"279","author":"Campbell","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib103","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.bcp.2004.10.014","article-title":"Role of two adjacent cytoplasmic tyrosine residues in MRP1 (ABCC1) transport activity and sensitivity to sulfonylureas","volume":"69","author":"Conseil","year":"2005","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib104","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1111\/j.2042-7158.1998.tb06918.x","article-title":"Efflux transport of tolbutamide across the blood-brain barrier","volume":"50","author":"Takanaga","year":"1998","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib105","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cbi.2015.09.006","article-title":"In vitro inhibition of AKR1Cs by sulphonylureas and the structural basis","volume":"240","author":"Zhao","year":"2015","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119009_bib106","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/1476-4598-9-141","article-title":"Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy","volume":"9","author":"Cottin","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib107","doi-asserted-by":"crossref","first-page":"371","DOI":"10.4172\/1948-5956.1000170","article-title":"Gap junction enhancer potentiates cytotoxicity of cisplatin in breast cancer cells","volume":"4","author":"Ding","year":"2012","journal-title":"J. Cancer Sci. Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib108","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bbrc.2007.08.066","article-title":"Connexin43 confers resistance to hydrogen peroxide-mediated apoptosis","volume":"362","author":"Giardina","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119009_bib109","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1074\/jbc.M113.508390","article-title":"Gap junction intercellular communication mediated by connexin43 in astrocytes is essential for their resistance to oxidative stress","volume":"289","author":"Le","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib110","first-page":"9","article-title":"Mechanisms involved in the regulation of the insulin secretory process","volume":"735","author":"Efendic","year":"1991","journal-title":"J. Intern. Med. Suppl."},{"key":"10.1016\/j.ejmech.2026.119009_bib111","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/0898-6568(90)90048-F","article-title":"Properties and functions of ATP-sensitive K-channels","volume":"2","author":"Ashcroft","year":"1990","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2026.119009_bib113","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0165-1218(80)90058-0","article-title":"Chlorpropamide inhibition of excision repair and postreplication repair of ultraviolet damage in Chinese hamster ovary cells","volume":"77","author":"Brown","year":"1980","journal-title":"Mutat. Res. Genet. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0165-1218(95)00070-4","article-title":"Revalidation of the in vitro alkaline elution\/rat hepatocyte assay for DNA damage: improved criteria for assessment of cytotoxicity and genotoxicity, and results for 81 compounds","volume":"368","author":"Storer","year":"1996","journal-title":"Mutat. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib115","first-page":"487","article-title":"The cytopathic effect of fibrinolytic agents and human placental fractions on HeLa cells, Ir","volume":"36","author":"Thornes","year":"1961","journal-title":"J. Med. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib116","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1210\/endo-116-2-660","article-title":"Inhibition of hormonal activation of hepatic phosphorylase by chlorpropamide: evidence for an intracellular site of drug action","volume":"116","author":"Blumenthal","year":"1985","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejmech.2026.119009_bib117","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.apsb.2021.08.007","article-title":"Anti-aging effects of chlorpropamide depend on mitochondrial complex-II and the production of mitochondrial reactive oxygen species","volume":"12","author":"Mao","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119009_bib118","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1055\/s-0028-1116944","article-title":"\u00dcber die Beeinflussung der Alkoholtoleranz durch blutzuckersenkende Harnstoffderivate","volume":"82","author":"Czyzyk","year":"1957","journal-title":"Dtsch. Med. Wochenschr."},{"key":"10.1016\/j.ejmech.2026.119009_bib119","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1749-6632.1959.tb39621.x","article-title":"Tolerance for alcohol in patients on chlorpropamide","volume":"74","author":"Signorelli","year":"1959","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib120","first-page":"286","article-title":"Elevation of plasma acetaldehyde: the first metabolic step in CPAF?","volume":"19","author":"Jerntorp","year":"1980","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.119009_bib121","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/bmj.283.6297.939","article-title":"Blood concentrations of acetaldehyde during chlorpropamide-alcohol flush","volume":"283","author":"Barnett","year":"1981","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2026.119009_bib122","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/0041-008X(85)90077-8","article-title":"Effect of tolbutamide and chlorpropamide on acetaldehyde metabolism in two inbred strains of mice","volume":"80","author":"Little","year":"1985","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib123","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1021\/jm00098a008","article-title":"Prodrugs of nitroxyl as inhibitors of aldehyde dehydrogenase","volume":"35","author":"Lee","year":"1992","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib124","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1006\/niox.2001.0349","article-title":"N-hydroxybenzenecarboximidic acid derivatives: a new class of nitroxyl-generating prodrugs","volume":"5","author":"Lee","year":"2001","journal-title":"Nitric Oxide"},{"key":"10.1016\/j.ejmech.2026.119009_bib125","first-page":"133","article-title":"Inhibition of human class 3 aldehyde dehydrogenase, and sensitization of tumor cells that express significant amounts of this enzyme to oxazaphosphorines, by the naturally occurring compound gossypol","volume":"414","author":"Rekha","year":"1997"},{"key":"10.1016\/j.ejmech.2026.119009_bib126","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0009-2797(01)00282-4","article-title":"Inhibition of ALDH3A1-catalyzed oxidation by chlorpropamide analogues","volume":"138","author":"Sladek","year":"2001","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119009_bib127","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/nature16932","article-title":"Naturally occurring p16\u02c6Ink4a-positive cells shorten healthy lifespan","volume":"530","author":"Baker","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119009_bib128","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/s41591-018-0092-9","article-title":"Senolytics improve physical function and increase lifespan in old age","volume":"24","author":"Xu","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib129","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1002\/cber.19570901116","article-title":"\u00dcber die Einwirkung von N-substituierten S\u00e4ureamiden auf Isocyanate, I","volume":"90","author":"Logemann","year":"1957","journal-title":"Chem. Ber."},{"key":"10.1016\/j.ejmech.2026.119009_bib130","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.saa.2008.01.005","article-title":"Synthesis, characterization and DNA-binding studies of 1-cyclohexyl-3-tosylurea and its Ni(II) and Cd(II) complexes","volume":"71","author":"Xi","year":"2008","journal-title":"Spectrochim. Acta Mol. Biomol. Spectrosc."},{"key":"10.1016\/j.ejmech.2026.119009_bib131","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1248\/cpb.56.541","article-title":"Synthesis, characterization, antioxidant activity, and DNA-binding studies of 1-cyclohexyl-3-tosylurea and its Nd(III), Eu(III) complexes","volume":"56","author":"Xi","year":"2008","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejmech.2026.119009_bib132","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1021\/jm01239a016","article-title":"Antidiabetic agents. N4-arylsulfonylsemicarbazides","volume":"5","author":"Wright","year":"1962","journal-title":"J. Med. Pharmaceut. Chem."},{"issue":"95","key":"10.1016\/j.ejmech.2026.119009_bib133","doi-asserted-by":"crossref","DOI":"10.1126\/scirobotics.adm8233","article-title":"Robotic manipulation of cardiomyocytes to identify gap junction modifiers for arrhythmogenic cardiomyopathy","volume":"9","author":"Dou","year":"2024","journal-title":"Sci. Robot."},{"issue":"4","key":"10.1016\/j.ejmech.2026.119009_bib134","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1097\/HEP.0000000000000025","article-title":"SULT2B1-CS-DOCK2 axis regulates effector T-cell exhaustion in HCC microenvironment","volume":"78","author":"Wang","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.ejmech.2026.119009_bib135","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40478-019-0712-8","article-title":"Inhibition of mitochondrial respiration prevents BRAF-mutant melanoma brain metastasis","volume":"7","author":"Sundstr\u00f8m","year":"2019","journal-title":"Acta Neuropathol. Commun."},{"issue":"765","key":"10.1016\/j.ejmech.2026.119009_bib136","first-page":"690","article-title":"Threshold Pharmaceuticals, Use of glucose-lowering agents in combination with glufosfamide for the treatment of tumors","volume":"8","year":"2014","journal-title":"U.S. Patent"},{"key":"10.1016\/j.ejmech.2026.119009_bib137","article-title":"Pharmaceutical compositions and methods for intratumoral drug delivery","year":"2024","journal-title":"Eur. Patent EP 4 188 359 B1"},{"key":"10.1016\/j.ejmech.2026.119009_bib138","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.neuropharm.2010.06.011","article-title":"Inhibition of ATP-sensitive potassium channels increases HSV-tk\/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication","volume":"59","author":"Pa\u00edno","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejmech.2026.119009_bib139","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1042\/bj2880675","article-title":"Evidence that GLUT-2 mRNA and protein concentrations are decreased by hyperinsulinaemia and increased by hyperglycaemia in liver of diabetic rats","volume":"288","author":"Burcelin","year":"1992","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2026.119009_bib140","first-page":"E548","article-title":"Development and regulation of glucose transporter and hexokinase expression in rat","volume":"266","author":"Postic","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib141","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s002590100517","article-title":"Effects of insulin and glucose loading on FDG uptake in experimental malignant tumours and inflammatory lesions","volume":"28","author":"Zhao","year":"2001","journal-title":"Eur. J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib142","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2967\/jnumed.108.056283","article-title":"Impact of intravenous insulin on 18F-FDG PET in diabetic cancer patients","volume":"50","author":"Roy","year":"2009","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib143","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1054\/bjoc.1999.0974","article-title":"Mechanistic aspects of the cytotoxic activity of glufosfamide, a new tumour therapeutic agent","volume":"82","author":"Seker","year":"2000","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib144","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1593\/neo.07343","article-title":"A novel alkylating agent, glufosfamide, enhances the activity of gemcitabine in vitro and in vivo","volume":"9","author":"Ammons","year":"2007","journal-title":"Neoplasia"},{"key":"10.1016\/j.ejmech.2026.119009_bib145","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1007\/s13300-024-01612-8","article-title":"Current position of gliclazide and sulfonylureas in the contemporary treatment paradigm for type 2 diabetes: a scoping review","volume":"15","author":"Sahin","year":"2024","journal-title":"Diabetes Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib146","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.665276","article-title":"Identification of prognostic signature and gliclazide as candidate drugs in lung adenocarcinoma","volume":"11","author":"Cheng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib147","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1492284","article-title":"Computational studies for pre-evaluation of pharmacological profile of gut microbiota-produced gliclazide metabolites","volume":"15","author":"\u0110ani\u0107","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib148","article-title":"Gliclazide charge transfer complexes with some benzoquinone acceptors: synthesis, structural characterization, thermal analyses, DFT studies, evaluation of anticancer activity","volume":"1238","author":"Abdallah","year":"2021","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.ejmech.2026.119009_bib149","first-page":"21","article-title":"Gliclazide, a KATP channel blocker, inhibits vascular smooth muscle cell proliferation through the CaMKK\u03b2-AMPK pathway, Vascul","volume":"102","author":"Lee","year":"2018","journal-title":"Pharmacologist"},{"key":"10.1016\/j.ejmech.2026.119009_bib150","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1093\/jb\/mvm172","article-title":"Gliclazide inhibits proliferation but stimulates differentiation of white and brown adipocytes","volume":"142","author":"Nakano","year":"2007","journal-title":"J. Biochem."},{"key":"10.1016\/j.ejmech.2026.119009_bib151","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.cbi.2006.07.006","article-title":"Effect of gliclazide on DNA damage in human peripheral blood lymphocytes and insulinoma mouse cells","volume":"162","author":"Sliwinska","year":"2006","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119009_bib152","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cbi.2008.03.017","article-title":"In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM)","volume":"173","author":"Sliwinska","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2026.119009_bib153","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1007\/s11033-011-1323-z","article-title":"Gliclazide may have an antiapoptotic effect related to its antioxidant properties in human normal and cancer cells","volume":"39","author":"Sliwinska","year":"2012","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib154","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0006-291X(03)00310-3","article-title":"Gliclazide protects pancreatic \u03b2-cells from damage by hydrogen peroxide","volume":"303","author":"Kimoto","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119009_bib155","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1046\/j.1464-5491.2002.00762.x","article-title":"Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in type 2 diabetes","volume":"19","author":"Fava","year":"2002","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib156","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1056-8727(00)00084-2","article-title":"In vitro and in vivo antioxidant properties of gliclazide","volume":"14","author":"O'Brien","year":"2000","journal-title":"J. Diabetes Complicat."},{"key":"10.1016\/j.ejmech.2026.119009_bib157","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1462-8902.2004.00320.x","article-title":"Signalling pathways involved in retinal endothelial cell proliferation induced by advanced glycation end products: inhibitory effect of gliclazide","volume":"6","author":"Mamputu","year":"2004","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.119009_bib158","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1046\/j.1463-1326.1999.00012.x","article-title":"Gliclazide reduces the induction of human monocyte adhesion to endothelial cells by glycated albumin","volume":"1","author":"Desfaits","year":"1999","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.119009_bib159","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0168-8227(99)00005-4","article-title":"Inhibition of tumor necrosis factor-alpha with anti-diabetic agents","volume":"43","author":"Fukuzawa","year":"1999","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib160","doi-asserted-by":"crossref","first-page":"H1507","DOI":"10.1152\/ajpheart.00886.2013","article-title":"Tempol improves cutaneous thermal hyperemia through increasing nitric oxide bioavailability in young smokers","volume":"306","author":"Fujii","year":"2014","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"issue":"Suppl. 2","key":"10.1016\/j.ejmech.2026.119009_bib161","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1186\/ar549","article-title":"How does infliximab work in rheumatoid arthritis?","volume":"4","author":"Maini","year":"2002","journal-title":"Arthritis Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib164","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/10837450802498894","article-title":"Co-solvent solubilization of some poorly-soluble antidiabetic drugs","volume":"14","author":"Seedher","year":"2009","journal-title":"Pharmaceut. Dev. Technol."},{"key":"10.1016\/j.ejmech.2026.119009_bib165","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1080\/03639045.2018.1431656","article-title":"Impact of various solid carriers and spray drying on pre\/post compression properties of solid SNEDDS loaded with glimepiride: in vitro-ex vivo evaluation and cytotoxicity assessment","volume":"44","author":"Rajesh","year":"2018","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"32","key":"10.1016\/j.ejmech.2026.119009_bib166","doi-asserted-by":"crossref","first-page":"19968","DOI":"10.1021\/acsomega.0c01228","article-title":"Physicochemical characterization, molecular docking, and in vitro dissolution of glimepiride-Captisol inclusion complexes","volume":"5","author":"Pal","year":"2020","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119009_bib167","first-page":"331","article-title":"Absolute bioavailability of glimepiride (Amaryl) after oral administration, Drug Metab","volume":"11","author":"Badian","year":"1994","journal-title":"Drug Interact."},{"key":"10.1016\/j.ejmech.2026.119009_bib168","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1365-2710.2006.00766.x","article-title":"Pharmacokinetic and pharmacodynamic modelling of the effects of glimepiride on insulin secretion and glucose lowering in healthy humans","volume":"31","author":"Yun","year":"2006","journal-title":"J. Clin. Pharm. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119009_bib169","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.chroma.2015.07.012","article-title":"Analysis of multi-site drug-protein interactions by high-performance affinity chromatography: binding by glimepiride to normal or glycated human serum albumin","volume":"1408","author":"Matsuda","year":"2015","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejmech.2026.119009_bib170","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jchromb.2018.10.015","article-title":"Binding studies based on ultrafast affinity extraction and single- or two-column systems: interactions of second- and third-generation sulfonylurea drugs with normal or glycated human serum albumin","volume":"1102\u20131103","author":"Yang","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejmech.2026.119009_bib171","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2004.05.008","article-title":"Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations","volume":"23","author":"Miro","year":"2004","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib172","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1039\/C8CE01848K","article-title":"Preparation and characterization for multicomponent crystals of the antidiabetic drug gliquidone based on crystal engineering","volume":"21","author":"Jia","year":"2019","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejmech.2026.119009_bib173","first-page":"1933","article-title":"Pharmakokinetisches Verhalten von gliquidone (AR-DF 26), einem neuen Sulfonylharnstoff (Zusammenfassung der bisherigen Untersuchungen)","volume":"25","author":"Kopitar","year":"1975","journal-title":"Arzneim.-Forsch."},{"key":"10.1016\/j.ejmech.2026.119009_bib174","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/open.202100246","article-title":"Solubility enhancement of antidiabetic drugs using a co-crystallization approach","volume":"10","author":"Batisai","year":"2021","journal-title":"ChemistryOpen"},{"key":"10.1016\/j.ejmech.2026.119009_bib175","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1208\/s12249-017-0727-z","article-title":"Stable co-crystals of glipizide with enhanced dissolution profiles: preparation and characterization","volume":"18","author":"Pandey","year":"2017","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejmech.2026.119009_bib176","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/j.1552-4604.1989.tb03289.x","article-title":"Glipizide pharmacokinetics: effects of age, diabetes, and multiple dosing","volume":"29","author":"Kradjan","year":"1989","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib177","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF00315518","article-title":"The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics","volume":"45","author":"Jaber","year":"1993","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib178","doi-asserted-by":"crossref","first-page":"9698","DOI":"10.3390\/ijms25179698","article-title":"In vitro spectroscopic investigation of losartan and glipizide competitive binding to glycated albumin: a comparative study","volume":"25","author":"Szkudlarek","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2023.123798","article-title":"Characterization of binding by sulfonylureas with normal or modified human serum albumin using affinity microcolumns prepared by entrapment","volume":"1226","author":"Poddar","year":"2023","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejmech.2026.119009_bib180","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/acs.cgd.7b00933","article-title":"Crystal engineering: a remedy to tailor the biopharmaceutical aspects of glibenclamide","volume":"18","author":"Goyal","year":"2018","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejmech.2026.119009_bib181","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1177\/106002809603000507","article-title":"Pharmacokinetics and pharmacodynamics of glyburide in young and elderly patients with non-insulin-dependent diabetes mellitus","volume":"30","author":"Jaber","year":"1996","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.ejmech.2026.119009_bib182","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0378-5173(87)90107-4","article-title":"Comparison of pharmacokinetics and pharmacodynamics of a conventional and a new rapidly dissolving glibenclamide preparation","volume":"38","author":"Shaheen","year":"1987","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119009_bib183","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.chroma.2014.10.092","article-title":"Analysis of free drug fractions by ultrafast affinity extraction: interactions of sulfonylurea drugs with normal or glycated human serum albumin","volume":"1371","author":"Zheng","year":"2014","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejmech.2026.119009_bib184","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1039\/C5CE02402A","article-title":"Novel cocrystals of gliclazide: characterization and evaluation","volume":"18","author":"Chadha","year":"2016","journal-title":"CrystEngComm"},{"key":"10.1016\/j.ejmech.2026.119009_bib185","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1021\/acs.cgd.6b01804","article-title":"Salts and cocrystals of the antidiabetic drugs gliclazide, tolbutamide, and glipizide: solubility enhancements through drug-coformer interactions","volume":"17","author":"Samie","year":"2017","journal-title":"Cryst. Growth Des."},{"key":"10.1016\/j.ejmech.2026.119009_bib186","first-page":"49","article-title":"Solubility enhancement of gliclazide via co-crystallization with malonic acid","volume":"16","author":"Ibrahim","year":"2019","journal-title":"Life Sci. J."},{"issue":"Suppl. 2","key":"10.1016\/j.ejmech.2026.119009_bib187","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/0168-8227(91)90005-X","article-title":"The mode of action and clinical pharmacology of gliclazide: a review","volume":"14","author":"Campbell","year":"1991","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib188","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1007\/s00216-011-5382-8","article-title":"High-performance affinity chromatography and the analysis of drug interactions with modified proteins: binding of gliclazide with glycated human serum albumin","volume":"401","author":"Matsuda","year":"2011","journal-title":"Anal. Bioanal. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib190","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/ph15030279","article-title":"Solids turn into liquids \u2013 liquid eutectic systems of pharmaceutics to improve drug solubility","volume":"15","author":"Sarragu\u00e7a","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119009_bib191","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.3109\/03639048709068694","article-title":"Dissolution of chlorpropamide tablets in a methanol-water binary solvent system","volume":"13","author":"Dodge","year":"1987","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejmech.2026.119009_bib192","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1007\/s11095-013-1278-y","article-title":"A novel method for determining the solubility of small molecules in aqueous media and polymer solvent systems using solution calorimetry","volume":"31","author":"Fadda","year":"2014","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib193","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jchromb.2018.09.001","article-title":"Chromatographic studies of chlorpropamide interactions with normal and glycated human serum albumin based on affinity microcolumns","volume":"1097\u20131098","author":"Tao","year":"2018","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.ejmech.2026.119009_bib194","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/jssc.201600713","article-title":"Study on the interactions of sulfonylurea antidiabetic drugs with normal and glycated human serum albumin by capillary electrophoresis-frontal analysis","volume":"39","author":"Michalcov\u00e1","year":"2016","journal-title":"J. Separ. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib195","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jpba.2010.09.003","article-title":"Binding of tolbutamide to glycated human serum albumin","volume":"54","author":"Joseph","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119009_bib196","series-title":"The AQUASOL Database of Aqueous Solubility","author":"Yalkowsky","year":"1992"},{"key":"10.1016\/j.ejmech.2026.119009_bib162","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1021\/cb300189b","article-title":"Colloidal aggregation affects the efficacy of anticancer drugs in cell culture","volume":"7","author":"Owen","year":"2012","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119009_bib163","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.nantod.2018.02.011","article-title":"Colloidal aggregation: from screening nuisance to formulation nuance","volume":"19","author":"Ganesh","year":"2018","journal-title":"Nano Today"},{"key":"10.1016\/j.ejmech.2026.119009_bib197","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2147\/IJN.S582548","article-title":"Recent advances in glimepiride solubility improvement: a focus on formulation technologies \u2013 a narrative review","volume":"21","author":"Fiftianingrum","year":"2026","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib198","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.3390\/pharmaceutics14091947","article-title":"Pharmacokinetics and anti-diabetic studies of gliclazide nanosuspension","volume":"14","author":"Sampathi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119009_bib199","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ijpharm.2010.12.027","article-title":"Physical stability of nanosuspensions: investigation of the role of stabilizers on Ostwald ripening","volume":"406","author":"Verma","year":"2011","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2026.119009_bib206","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/j.cell.2017.01.041","article-title":"Structural basis of substrate recognition by the multidrug resistance protein MRP1","volume":"168","author":"Johnson","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119009_bib207","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/j.cell.2016.11.014","article-title":"Atomic structure of the cystic fibrosis transmembrane conductance regulator","volume":"167","author":"Zhang","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.119009_bib208","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nature11448","article-title":"Crystal structure of the multidrug transporter P-glycoprotein from Caenorhabditis elegans","volume":"490","author":"Jin","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119009_bib209","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.46417","article-title":"Mechanism of pharmacochaperoning in a mammalian KATP channel revealed by cryo-EM","volume":"8","author":"Martin","year":"2019","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119009_bib200","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1085\/jgp.201711978","article-title":"Cryo-electron microscopy structures and progress toward a dynamic understanding of KATP channels","volume":"150","author":"Puljung","year":"2018","journal-title":"J. Gen. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib201","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s13238-018-0530-y","article-title":"Ligand binding and conformational changes of SUR1 subunit in pancreatic ATP-sensitive potassium channels","volume":"9","author":"Wu","year":"2018","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2026.119009_bib202","doi-asserted-by":"crossref","first-page":"2770","DOI":"10.1038\/s41467-022-30430-4","article-title":"Structural insights into the mechanism of pancreatic KATP channel regulation by nucleotides","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119009_bib203","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.24149","article-title":"Cryo-EM structure of the ATP-sensitive potassium channel illuminates mechanisms of assembly and gating","volume":"6","author":"Martin","year":"2017","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119009_bib204","first-page":"710","article-title":"Recent advances in the search of BCRP- and dual P-gp\/BCRP-based multidrug resistance modulators","volume":"2","author":"Dei","year":"2019","journal-title":"Cancer Drug Resist."},{"key":"10.1016\/j.ejmech.2026.119009_bib205","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1002\/prot.26406","article-title":"Plastic structures for diverse substrates: a revisit of human ABC transporters","volume":"90","author":"Hou","year":"2022","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2026.119009_bib210","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1182\/blood.V90.8.2911","article-title":"Interleukin-1\u03b2 secretion is impaired by inhibitors of the ATP binding cassette transporter, ABC1","volume":"90","author":"Hamon","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2026.119009_bib211","doi-asserted-by":"crossref","first-page":"23742","DOI":"10.1074\/jbc.M102348200","article-title":"ATP-binding cassette transporter A1 functions as a cholesterol efflux regulatory protein","volume":"276","author":"Wang","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib212","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1194\/jlr.M300358-JLR200","article-title":"Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide","volume":"45","author":"Nieland","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib213","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s004240050829","article-title":"P-glycoprotein inhibition by glibenclamide and related compounds","volume":"437","author":"Golstein","year":"1999","journal-title":"Pflugers Arch. Eur. J. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib214","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/dmd.110.036160","article-title":"Endoxifen, the active metabolite of tamoxifen, is a substrate of the efflux transporter P-glycoprotein (multidrug resistance 1)","volume":"39","author":"Teft","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejmech.2026.119009_bib215","doi-asserted-by":"crossref","first-page":"26062","DOI":"10.1016\/S0021-9258(18)35717-X","article-title":"Reconstitution and partial purification of the glibenclamide-sensitive, ATP-dependent K+ channel from rat liver and beef heart mitochondria","volume":"267","author":"Paucek","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib216","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s002329900331","article-title":"Membrane potassium channels and human bladder tumor cells. I. Electrical properties","volume":"161","author":"Monen","year":"1998","journal-title":"J. Membr. Biol."},{"key":"10.1016\/j.ejmech.2026.119009_bib217","first-page":"261","article-title":"Blockage of voltage-gated K+ channels inhibits adhesion and proliferation of hepatocarcinoma cells","volume":"11","author":"Zhou","year":"2003","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib218","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0304-3835(02)00348-8","article-title":"Expression and activity of potassium ion channels in human prostate cancer","volume":"186","author":"Abdul","year":"2002","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.119009_bib219","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3892\/or.2013.2875","article-title":"Voltage-gated and ATP-sensitive K+ channels are associated with cell proliferation and tumorigenesis of human glioma","volume":"31","author":"Ru","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib220","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0304-3940(92)90130-Y","article-title":"Glibenclamide inhibits a voltage-gated K+ current in the human neuroblastoma cell line SH-SY5Y","volume":"135","author":"Reeve","year":"1992","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejmech.2026.119009_bib221","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ygyno.2006.08.033","article-title":"Voltage-gated K+ channels are associated with cell proliferation and cell cycle of ovarian cancer cell","volume":"104","author":"Weng","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104778","article-title":"Glibenclamide inhibits BK polyomavirus infection in kidney cells through CFTR blockade","volume":"178","author":"Panou","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib223","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1469-7793.1997.333bh.x","article-title":"Mechanism of glibenclamide inhibition of cystic fibrosis transmembrane conductance regulator Cl\u2212 channels expressed in a murine cell line","volume":"503","author":"Sheppard","year":"1997","journal-title":"J. Physiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib224","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1006\/bbrc.1999.1108","article-title":"Glibenclamide induces apoptosis through inhibition of cystic fibrosis transmembrane conductance regulator (CFTR) Cl\u2212 channels and intracellular Ca2+ release in HepG2 human hepatoblastoma cells","volume":"261","author":"Kim","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2026.119009_bib225","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/IGC.0b013e3181a3d6d2","article-title":"Regulation of ovarian cancer cell adhesion and invasion by chloride channels","volume":"19","author":"Li","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib226","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3390\/ph17030299","article-title":"Implications of NLRP3 suppression using glibenclamide and miR-223 against colorectal cancer","volume":"17","author":"Hamza","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"21","key":"10.1016\/j.ejmech.2026.119009_bib227","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111640","article-title":"Glyburide suppresses inflammation-related colorectal tumorigenesis through inhibition of NLRP3 inflammasome","volume":"25","author":"Maeda","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib228","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1007\/s00210-019-01773-5","article-title":"NLRP3 inhibitor glibenclamide attenuates high-fat diet and streptozotocin-induced non-alcoholic fatty liver disease in rat: studies on oxidative stress, inflammation, DNA damage and insulin signalling pathway","volume":"393","author":"Dwivedi","year":"2020","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.ejmech.2026.119009_bib229","series-title":"Glufosfamide Combination Therapy, Patent WO 2008 124691 A1","year":"2008"},{"key":"10.1016\/j.ejmech.2026.119009_bib230","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3727\/096504005776404526","article-title":"Effect of glibenclamide on N-nitroso-N-methylurea-induced mammary tumors in diabetic and nondiabetic rats","volume":"15","author":"Cocca","year":"2005","journal-title":"Oncol. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib231","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.3892\/ijo.2012.1483","article-title":"Depolarization potentiates TRAIL-induced apoptosis in human melanoma cells: role for ATP-sensitive K+ channels and endoplasmic reticulum stress","volume":"41","author":"Suzuki","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib232","series-title":"Pharmaceutical Combinations for the Treatment of Cancer, Patent WO 2015 061832 A1","year":"2015"},{"key":"10.1016\/j.ejmech.2026.119009_bib233","first-page":"141","article-title":"Uncoupling effect of hypoglycemic sulphonylureas on the isolated rat liver mitochondria","volume":"35","author":"Katsumata","year":"1973","journal-title":"Nagoya J. Med. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib234","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/jbt.20022","article-title":"Glibenclamide interferes with mitochondrial bioenergetics by inducing changes on membrane ion permeability","volume":"18","author":"Fernandes","year":"2004","journal-title":"J. Biochem. Mol. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib235","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/sj.bjp.0706214","article-title":"Antidiabetic sulphonylureas activate mitochondrial permeability transition in rat skeletal muscle","volume":"145","author":"Skalska","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib236","doi-asserted-by":"crossref","first-page":"50821","DOI":"10.1021\/acsami.3c10940","article-title":"Endoplasmic reticulum-targeted aggregation-induced emission luminogen for synergetic tumor ablation with glibenclamide","volume":"15","author":"Wu","year":"2023","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.ejmech.2026.119009_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2020.113400","article-title":"The new role of F1Fo ATP synthase in mitochondria-mediated neurodegeneration and neuroprotection","volume":"332","author":"Mnatsakanyan","year":"2020","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejmech.2026.119009_bib238","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2022111699","article-title":"Inhibition of ATP synthase reverse activity restores energy homeostasis in mitochondrial pathologies","volume":"42","author":"Acin-Perez","year":"2023","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2026.119009_bib239","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/0304-4165(70)90024-3","article-title":"Decrease of the hepatic ATP content and gluconeogenesis in ethionine-treated rats","volume":"215","author":"Tani","year":"1970","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2026.119009_bib240","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1006\/abbi.1993.1357","article-title":"Adenine nucleotides and inhibition of protein synthesis in isolated hepatocytes incubated under different pO2 levels","volume":"304","author":"Lefebvre","year":"1993","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2026.119009_bib241","doi-asserted-by":"crossref","first-page":"eaan2883","DOI":"10.1126\/scisignal.aan2883","article-title":"TALK-1 channels control \u03b2 cell endoplasmic reticulum Ca2+ homeostasis","volume":"10","author":"Vierra","year":"2017","journal-title":"Sci. Signal."},{"key":"10.1016\/j.ejmech.2026.119009_bib242","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/j.bcp.2008.09.009","article-title":"Glibenclamide exerts an antitumor activity through reactive oxygen species-c-Jun NH2-terminal kinase pathway in human gastric cancer cell line MGC-803","volume":"76","author":"Qian","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib243","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20170685","article-title":"Glibenclamide induces apoptosis by activating reactive oxygen species-dependent JNK pathway in hepatocellular carcinoma cells","volume":"37","author":"Yan","year":"2017","journal-title":"Biosci. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib244","article-title":"The antagonistic atorvastatin-glibenclamide interactions suppressed the atorvastatin-induced Bax\/cytochrome c\/p53 mRNA expressions and increased Rho A mRNA expression in B16f10 melanoma cell culture","volume":"23","author":"Malek","year":"2021","journal-title":"Gene Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ab.2006.06.018","article-title":"Blocking cardiac ATP-sensitive K+ channels reduces hydroxyl radicals caused by potassium chloride-induced depolarization in the rat myocardium","volume":"356","author":"Obata","year":"2006","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.ejmech.2026.119009_bib246","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.febslet.2012.04.007","article-title":"Suppression of cellular invasion by glybenclamide through inhibited secretion of platelet-derived growth factor in ovarian clear cell carcinoma ES-2 cells","volume":"586","author":"Yasukagawa","year":"2012","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2026.119009_bib247","doi-asserted-by":"crossref","first-page":"5415","DOI":"10.1021\/acs.jmedchem.2c01663","article-title":"Structural dynamics-driven discovery of anticancer and antimetastatic effects of diltiazem and glibenclamide targeting urokinase receptor","volume":"66","author":"Zhou","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib248","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3892\/mmr.2013.1704","article-title":"A novel four-step system for screening angiogenesis inhibitors","volume":"8","author":"Zhou","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib249","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.yexcr.2015.03.012","article-title":"Glipizide suppresses embryonic vasculogenesis and angiogenesis through targeting natriuretic peptide receptor A","volume":"333","author":"Gu","year":"2015","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib250","doi-asserted-by":"crossref","DOI":"10.1038\/srep27819","article-title":"Glipizide suppresses prostate cancer progression in the TRAMP model by inhibiting angiogenesis","volume":"6","author":"Qi","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib251","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2174\/1871520621666210910085733","article-title":"Glipizide combined with ANP suppresses breast cancer growth and metastasis by inhibiting angiogenesis through VEGF\/VEGFR2 signaling","volume":"22","author":"Mao","year":"2022","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib252","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10753-023-01850-1","article-title":"Glipizide alleviates periodontitis pathogenicity via inhibition of angiogenesis, osteoclastogenesis and M1\/M2 macrophage ratio in periodontal tissue","volume":"46","author":"Guo","year":"2023","journal-title":"Inflammation"},{"key":"10.1016\/j.ejmech.2026.119009_bib253","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.131573","article-title":"Exploring the mechanism of interaction of glipizide with DNA: combined in vitro and bioinformatics approach","volume":"267","author":"Qais","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ejmech.2026.119009_bib254","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s11033-021-06942-5","article-title":"The effects of glipizide on DNA damage and nuclear transport in differentiated 3T3-L1 adipocytes","volume":"49","author":"Cevik","year":"2022","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib255","doi-asserted-by":"crossref","first-page":"100021","DOI":"10.18632\/oncotarget.21754","article-title":"Glipizide sensitizes lung cancer cells to TRAIL-induced apoptosis via Akt\/mTOR\/autophagy pathways","volume":"8","author":"Nazim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119009_bib256","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-2999(99)00128-4","article-title":"Pharmacological and molecular characterization of ATP-sensitive K+ channels in the TE671 human medulloblastoma cell line","volume":"370","author":"Miller","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib257","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s12264-007-0021-2","article-title":"Pinacidil reduces neuronal apoptosis following cerebral ischemia-reperfusion in rats through both mitochondrial and death-receptor signal pathways","volume":"23","author":"Zhang","year":"2007","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.ejmech.2026.119009_bib258","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4093\/dmj.2011.35.4.340","article-title":"Effects of sulfonylureas on peroxisome proliferator-activated receptor \u03b3 activity and on glucose uptake by thiazolidinediones","volume":"35","author":"Lee","year":"2011","journal-title":"Diabetes Metab. J"},{"key":"10.1016\/j.ejmech.2026.119009_bib259","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3389\/fonc.2014.00159","article-title":"The activity of SN33638, an inhibitor of AKR1C3, on testosterone and 17\u03b2-estradiol production and function in castration-resistant prostate cancer and ER-positive breast cancer","volume":"4","author":"Yin","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib260","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.3390\/cancers12082092","article-title":"Dual inhibitory action of a novel AKR1C3 inhibitor on both full-length AR and the variant AR-V7 in enzalutamide-resistant prostate cancer","volume":"12","author":"Kafka","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119009_bib261","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1124\/mol.106.024596","article-title":"Sulfonylureas and glinides exhibit peroxisome proliferator-activated receptor \u03b3 activity: a combined virtual screening and biological assay approach","volume":"71","author":"Scarsi","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib262","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2021.754123","article-title":"The anti-diabetic drug gliquidone modulates lipopolysaccharide-mediated microglial neuroinflammatory responses by inhibiting the NLRP3 inflammasome","volume":"13","author":"Kim","year":"2021","journal-title":"Front. Aging Neurosci."},{"key":"10.1016\/j.ejmech.2026.119009_bib263","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/cmdc.201700270","article-title":"Sulfonylureas as concomitant insulin secretagogues and NLRP3 inflammasome inhibitors","volume":"12","author":"Hill","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119009_bib264","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1159\/000495827","article-title":"Gliquidone alleviates diabetic nephropathy by inhibiting Notch\/Snail signaling pathway","volume":"51","author":"Tian","year":"2018","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.ejmech.2026.119009_bib265","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1186\/s12886-021-02215-8","article-title":"Gliquidone improves retinal injury to relieve diabetic retinopathy via regulation of SIRT1\/Notch1 pathway","volume":"21","author":"Yu","year":"2021","journal-title":"BMC Ophthalmol."},{"key":"10.1016\/j.ejmech.2026.119009_bib266","article-title":"Synergistic inhibitory effect of gliquidone against cisplatin-resistant human lung adenocarcinoma","volume":"2024","author":"Qiu","year":"2024","journal-title":"J. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib267","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1471-2369-11-31","article-title":"Bone morphogenetic protein-7 expression is decreased in human hypertensive nephrosclerosis","volume":"11","author":"Bramlage","year":"2010","journal-title":"BMC Nephrol."},{"key":"10.1016\/j.ejmech.2026.119009_bib268","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/nm888","article-title":"BMP-7 counteracts TGF-\u03b21-induced epithelial-to-mesenchymal transition and reverses chronic renal injury","volume":"9","author":"Zeisberg","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib269","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.biocel.2010.03.016","article-title":"Notch mediated epithelial to mesenchymal transformation is associated with increased expression of the Snail transcription factor","volume":"42","author":"Saad","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.ejmech.2026.119009_bib270","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1172\/JCI1244","article-title":"PPAR\u03b3 induces the insulin-dependent glucose transporter GLUT4 in the absence of C\/EBP\u03b1 during the conversion of 3T3 fibroblasts into adipocytes","volume":"101","author":"Wu","year":"1998","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejmech.2026.119009_bib271","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0969-9961(02)00017-7","article-title":"Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration","volume":"12","author":"Arimoto","year":"2003","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejmech.2026.119009_bib272","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00109-013-1090-5","article-title":"The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia","volume":"92","author":"Przanowski","year":"2014","journal-title":"J. Mol. Med. (Berl.)"},{"key":"10.1016\/j.ejmech.2026.119009_bib273","first-page":"966","article-title":"COX-2 contributes to LPS-induced Stat3 activation and IL-6 production in microglial cells","volume":"10","author":"Zhu","year":"2018","journal-title":"Am. J. Transl. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib274","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/bjc.2014.386","article-title":"Glutathione S-transferase P1 (GSTP1) directly influences platinum drug chemosensitivity in ovarian tumour cell lines","volume":"111","author":"Sawers","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib275","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/cbf.3577","article-title":"Increased ABCC2 expression predicts cisplatin resistance in non-small cell lung cancer","volume":"39","author":"Chen","year":"2021","journal-title":"Cell Biochem. Funct."},{"key":"10.1016\/j.ejmech.2026.119009_bib276","first-page":"4376","article-title":"Treatment with 20(S)-ginsenoside Rg3 reverses multidrug resistance in A549\/DDP xenograft tumors","volume":"15","author":"Liu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2026.119009_bib277","doi-asserted-by":"crossref","first-page":"4442","DOI":"10.1038\/s41467-026-71108-5","article-title":"Lactylation at lysine 145 fosters KAT8\u2013TIP60 complex formation to promote p53 acetylation at lysine 120 and its pro-apoptotic function","volume":"17","author":"Liu","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119009_bib278","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s44411-024-00015-2","article-title":"Sulfonylureas glimepiride and gliclazide prevent pancreatic cancer progression by modulating Capn2 and strengthening tumor immunotherapy","volume":"126","author":"Chen","year":"2025","journal-title":"Bratisl. Med. J."},{"key":"10.1016\/j.ejmech.2026.119009_bib279","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/2651790","article-title":"The effects of 6 common antidiabetic drugs on anti-PD1 immune checkpoint inhibitor in tumor treatment","volume":"2022","author":"Zhan","year":"2022","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib280","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.2147\/OTT.S240252","article-title":"The anti-breast cancer effect and mechanism of glimepiride-metformin adduct","volume":"13","author":"Long","year":"2020","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib281","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib282","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1046\/j.1365-2184.2003.00290.x","article-title":"Over-expression of cyclin D1 regulates Cdk4 protein synthesis","volume":"36","author":"Parker","year":"2003","journal-title":"Cell Prolif."},{"key":"10.1016\/j.ejmech.2026.119009_bib283","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02872","article-title":"Cyclin D activates the Rb tumor suppressor by mono-phosphorylation","volume":"3","author":"Narasimha","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.ejmech.2026.119009_bib284","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.molcel.2019.03.020","article-title":"Cyclin D-Cdk4,6 drives cell-cycle progression via the retinoblastoma protein's C-terminal helix","volume":"74","author":"Topacio","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119009_bib285","doi-asserted-by":"crossref","DOI":"10.1016\/j.tiv.2021.105128","article-title":"A potential role of calpains in sulfonylureas (SUs)-mediated death of human pancreatic cancer cells (1.2B4)","volume":"73","author":"Szymczak-Pajor","year":"2021","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2026.119009_bib286","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/bjd.17253","article-title":"Novel therapeutic approaches to xeroderma pigmentosum","volume":"181","author":"Weon","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.ejmech.2026.119009_bib287","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0123979","article-title":"MMP7 is required to mediate cell invasion and tumor formation upon Plakophilin3 loss","volume":"10","author":"Basu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119009_bib288","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s10238-012-0212-7","article-title":"Knockdown of MMP-7 inhibits cell proliferation and enhances sensitivity to 5-fluorouracil and X-ray irradiation in colon cancer cells","volume":"14","author":"Zhang","year":"2014","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib289","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.3390\/cancers14143437","article-title":"A novel ALDH1A1 inhibitor blocks platinum-induced senescence and stemness in ovarian cancer","volume":"14","author":"Muralikrishnan","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119009_bib290","article-title":"Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells","volume":"3","author":"Chen","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119009_bib291","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/sj.cdd.4401592","article-title":"Ceramide triggers an NF-\u03baB-dependent survival pathway through calpain","volume":"12","author":"Demarchi","year":"2005","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.ejmech.2026.119009_bib292","doi-asserted-by":"crossref","first-page":"162","DOI":"10.3389\/fonc.2014.00162","article-title":"AKR1C3 inhibition therapy in castration-resistant prostate cancer and breast cancer: lessons from responses to SN33638","volume":"4","author":"Zhou","year":"2014","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib293","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/bjc.2012.580","article-title":"In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen","volume":"108","author":"Kretschy","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib294","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2017.10.021","article-title":"Repair of UV-induced DNA damage independent of nucleotide excision repair is masked by MUTYH","volume":"68","author":"Mazouzi","year":"2017","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2026.119009_bib295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.dnarep.2019.05.005","article-title":"When you\u2019re strange: unusual features of the MUTYH glycosylase and implications in cancer","volume":"80","author":"Raetz","year":"2019","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2026.119009_bib296","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0312100","article-title":"Repurposing of drug candidates against Epstein-Barr virus: virtual screening, docking computations, molecular dynamics, and quantum mechanical study","volume":"19","author":"Ibrahim","year":"2024","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119009_bib297","first-page":"1800","article-title":"Screening and analysis of possible drugs binding to PDGFR\u03b1: a molecular modeling study","volume":"20","author":"Mozzicafreddo","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib298","first-page":"338","article-title":"Inhibition of Rho-associated kinase reduces MLC20 phosphorylation and contractility of intact myometrium and attenuates agonist-induced Ca2+ sensitization of force of permeabilized rat myometrium","volume":"99","author":"Oh","year":"2005","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2026.119009_bib299","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5612","article-title":"Structure-based design of small-molecule inhibitors of Epstein-Barr virus nuclear antigen 1 dimerization and DNA binding","volume":"11","author":"Messick","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib300","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/OTT.S62946","article-title":"CP-673451, a platelet-derived growth factor receptor inhibitor, suppresses lung cancer cell proliferation and migration","volume":"7","author":"Xi","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib301","first-page":"124","article-title":"[Erythrodermia secondary to an intense photosensitization caused by carbutamide (BZ 55)]","volume":"69","author":"Temime","year":"1962","journal-title":"Bull. Soc. Fr. Dermatol. Syphiligr."},{"key":"10.1016\/j.ejmech.2026.119009_bib302","first-page":"25","article-title":"Photodermatitis induced by chlorpropamide: a report of five cases","volume":"146","author":"Feuerman","year":"1973","journal-title":"Dermatologica (Basel)"},{"key":"10.1016\/j.ejmech.2026.119009_bib303","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1001\/jama.1962.03050140064017a","article-title":"Photosensitivity due to chlorpropamide","volume":"180","author":"Hitselberger","year":"1962","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.119009_bib304","first-page":"289","article-title":"Tolbutamide photosensitivity","volume":"82","author":"Kar","year":"1984","journal-title":"J. Indian Med. Assoc."},{"key":"10.1016\/j.ejmech.2026.119009_bib305","first-page":"42","article-title":"Photosensitivity due to glyburide","volume":"5","author":"Sun","year":"1988","journal-title":"Photo Dermatol."},{"key":"10.1016\/j.ejmech.2026.119009_bib306","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/ange.19800920822","article-title":"Photochemie von Sulfonamiden und Sulfonylharnstoffen: Ein Beitrag zum Problem der Lichtdermatosen","volume":"92","author":"Weiss","year":"1980","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejmech.2026.119009_bib307","first-page":"1079","article-title":"Photodegradation and in vitro phototoxicity of the antidiabetic drug chlorpropamide","volume":"45","author":"Vargas","year":"1995","journal-title":"Arzneim.-Forsch."},{"key":"10.1016\/j.ejmech.2026.119009_bib308","first-page":"3","article-title":"Studies on the in vitro phototoxicity of the antidiabetes drug gliclazide","volume":"1","author":"Vargas","year":"2006","journal-title":"Av. Qu\u00edm."},{"key":"10.1016\/j.ejmech.2026.119009_bib309","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1600-0781.1996.tb00179.x","article-title":"Photodegradation products of sulphonamide-derived oral antidiabetics and diuretics are not phototoxic in vitro","volume":"12","author":"Selvaag","year":"1996","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib310","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0781.1996.tb00235.x","article-title":"Phototoxicity due to sulphonamide-derived oral antidiabetics and diuretics: investigations in a cell culture model","volume":"12","author":"Selvaag","year":"1996","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib311","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/15569529709048889","article-title":"In vitro phototoxicity due to sulfonamide-derived oral antidiabetic and diuretic drugs","volume":"16","author":"Selvaag","year":"1997","journal-title":"J. Toxicol. Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib312","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1011-1344(96)07433-7","article-title":"Inhibiting effects of antioxidants on drug-induced phototoxicity in cell cultures: investigations with sulphonamide-derived oral antidiabetics and diuretics","volume":"38","author":"Selvaag","year":"1997","journal-title":"J. Photochem. Photobiol., B"},{"key":"10.1016\/j.ejmech.2026.119009_bib313","first-page":"103","article-title":"Phototoxicity to sulphonamide-derived oral antidiabetics and diuretics: comparative in vitro and in vivo investigations","volume":"11","author":"Selvaag","year":"1997","journal-title":"Vivo"},{"key":"10.1016\/j.ejmech.2026.119009_bib314","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/15569529709048900","article-title":"Photohemolysis due to oral antidiabetic drugs","volume":"16","author":"Selvaag","year":"1997","journal-title":"J. Toxicol. Cutan. Ocul. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib315","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1111\/j.1600-0781.1996.tb00194.x","article-title":"Photohemolytic potency of oral antidiabetic drugs in vitro: effects of antioxidants and a nitrogen atmosphere","volume":"12","author":"Selvaag","year":"1996","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib316","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0781.1997.tb00100.x","article-title":"Phototoxicity to sulphonamide-derived oral antidiabetics and diuretics: investigations in hairless mice","volume":"13","author":"Selvaag","year":"1997","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib317","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1034\/j.1600-0781.2002.180206.x","article-title":"Phototoxicity to diuretics and antidiabetics in the cultured keratinocyte cell line HaCaT: evaluation by clonogenic assay and single cell gel electrophoresis (Comet assay)","volume":"18","author":"Selvaag","year":"2002","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib318","first-page":"768","article-title":"High-throughput screening strategy for photogenotoxic potential of pharmaceutical substances using fluorescent intercalating dye","volume":"50","author":"Seto","year":"2009","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejmech.2026.119009_bib319","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.tiv.2013.05.008","article-title":"Development of micellar reactive oxygen species assay for photosafety evaluation of poorly water-soluble chemicals","volume":"27","author":"Seto","year":"2013","journal-title":"Toxicol. Vitro"},{"key":"10.1016\/j.ejmech.2026.119009_bib320","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/jat.2846","article-title":"Development of an albuminous reactive oxygen species assay for photosafety evaluation under experimental biomimetic conditions","volume":"34","author":"Onoue","year":"2014","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib321","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/jat.4569","article-title":"Modified ESR-based photosafety test (ESR-PT) detecting singlet oxygen and free radical formation","volume":"44","author":"Hinoshita","year":"2024","journal-title":"J. Appl. Toxicol."},{"key":"10.1016\/j.ejmech.2026.119009_bib322","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1055\/s-2007-979829","article-title":"An overview of the safety and tolerance of glimepiride","volume":"28","author":"Schneider","year":"1996","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib323","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1002\/dmrr.235","article-title":"Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide","volume":"17","author":"Holstein","year":"2001","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119009_bib324","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2362.2004.01381.x","article-title":"GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients","volume":"34","author":"Schernthaner","year":"2004","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ejmech.2026.119009_bib325","article-title":"Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study","volume":"354","author":"van Dalem","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejmech.2026.119009_bib326","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1002\/dmrr.971","article-title":"Sulfonylurea use and prognosis after myocardial infarction in patients with diabetes","volume":"25","author":"Horsdal","year":"2009","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119009_bib327","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.diabres.2009.09.008","article-title":"Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study","volume":"86","author":"Khalangot","year":"2009","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib328","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.2337\/dc10-0017","article-title":"The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis","volume":"33","author":"Pantalone","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib329","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1210\/jc.2010-0449","article-title":"Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction","volume":"95","author":"Zeller","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2026.119009_bib330","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.diabres.2011.07.011","article-title":"Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure","volume":"94","author":"Andersson","year":"2011","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib331","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1093\/eurheartj\/ehr077","article-title":"Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study","volume":"32","author":"Schramm","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.119009_bib332","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/dom.13168","article-title":"Risk of a first-ever acute myocardial infarction and all-cause mortality with sulphonylurea treatment: a population-based cohort study","volume":"20","author":"van Dalem","year":"2018","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.119009_bib333","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.diabres.2019.04.032","article-title":"Comparison of mortality and cardiovascular event risk associated with various insulin secretagogues: a nationwide real-world analysis","volume":"152","author":"Huang","year":"2019","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib334","article-title":"Gliclazide monotherapy increases risks of all-cause mortality and has similar risk of acute myocardial infarction and stroke with glimepiride monotherapy in Korean type 2 diabetes mellitus","volume":"99","author":"Cho","year":"2020","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejmech.2026.119009_bib335","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.23067","article-title":"Cardiovascular events in individuals treated with sulfonylureas or dipeptidyl peptidase 4 inhibitors","volume":"8","author":"Turchin","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.ejmech.2026.119009_bib336","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/s00592-008-0083-2","article-title":"Sulphonylureas and cancer: a case-control study","volume":"46","author":"Monami","year":"2009","journal-title":"Acta Diabetol."},{"key":"10.1016\/j.ejmech.2026.119009_bib337","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1158\/1055-9965.EPI-19-1517","article-title":"Is gliclazide associated with a lower obesity-related cancer risk compared to other sulfonylureas? A long-term prospective cohort study","volume":"29","author":"Du","year":"2020","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.ejmech.2026.119009_bib338","doi-asserted-by":"crossref","DOI":"10.1016\/j.canep.2019.101658","article-title":"Anti-diabetic medications and the risk for colorectal cancer: a population-based nested case-control study","volume":"64","author":"Shin","year":"2020","journal-title":"Cancer Epidemiol."},{"key":"10.1016\/j.ejmech.2026.119009_bib339","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/BF00542144","article-title":"Diabetic control with gliquidone \u2014 a short acting sulphonylurea","volume":"26","author":"Borthwick","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib340","doi-asserted-by":"crossref","first-page":"26","DOI":"10.5414\/CNP70026","article-title":"Gliquidone therapy of new-onset diabetes mellitus after kidney transplantation","volume":"70","author":"Tuerk","year":"2008","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.ejmech.2026.119009_bib341","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1532-5415.1996.tb03729.x","article-title":"Individual sulfonylureas and serious hypoglycemia in older people","volume":"44","author":"Shorr","year":"1996","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.ejmech.2026.119009_bib342","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/clpt.2010.74","article-title":"Anti-infectives and the risk of severe hypoglycemia in users of glipizide or glyburide","volume":"88","author":"Schelleman","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib343","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.diabres.2010.08.022","article-title":"Use of sulphonylurea and cancer in type 2 diabetes\u2014The Hong Kong diabetes registry","volume":"90","author":"Yang","year":"2010","journal-title":"Diabetes Res. Clin. Pract."},{"key":"10.1016\/j.ejmech.2026.119009_bib344","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)","volume":"352","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2026.119009_bib345","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1111\/j.1464-5491.2012.03772.x","article-title":"Adverse cardiovascular events during treatment with glyburide (glibenclamide) or gliclazide in a high-risk population","volume":"29","author":"Juurlink","year":"2012","journal-title":"Diabet. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib346","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/dmrr.736","article-title":"Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality","volume":"23","author":"Monami","year":"2007","journal-title":"Diabet. Metab. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119009_bib347","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1530\/EJE-13-0299","article-title":"Mortality outcomes of different sulphonylurea drugs: the results of a 14-year cohort study of type 2 diabetic patients","volume":"169","author":"Bo","year":"2013","journal-title":"Eur. J. Endocrinol."},{"key":"10.1016\/j.ejmech.2026.119009_bib348","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.2337\/dc15-1358","article-title":"The use of glyburide compared with other sulfonylureas and the risk of cancer in patients with type 2 diabetes","volume":"38","author":"Tuccori","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib349","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1002\/cpt1969103423","article-title":"Tolazamide (Tolinase)","volume":"10","year":"1969","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib350","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/bmj.1.5387.868","article-title":"Acetohexamide in treatment of diabetes mellitus","volume":"1","author":"Montgomery","year":"1964","journal-title":"Br. Med. J."},{"key":"10.1016\/j.ejmech.2026.119009_bib351","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jama.1965.03090100005001","article-title":"Long-term use of chlorpropamide in diabetes","volume":"193","author":"Cervantes-Amezcua","year":"1965","journal-title":"JAMA"},{"issue":"Suppl. 2","key":"10.1016\/j.ejmech.2026.119009_bib352","first-page":"789","article-title":"A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results","volume":"19","author":"Meinert","year":"1970","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib368","series-title":"Micronase\u00ae (Glyburide Tablets, USP)","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119009_bib366","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s002280050403","article-title":"Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function","volume":"53","author":"J\u00f6nsson","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib370","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.2337\/diabetes.47.9.1412","article-title":"Tissue specificity of sulfonylureas: studies on cloned cardiac and beta-cell K(ATP) channels","volume":"47","author":"Gribble","year":"1998","journal-title":"Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib371","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/sj.bjp.0702763","article-title":"Structural requirements of sulphonylureas and analogues for interaction with sulphonylurea receptor subtypes","volume":"128","author":"Meyer","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib367","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.2337\/diacare.17.9.1026","article-title":"Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans","volume":"17","author":"Rydberg","year":"1994","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib369","series-title":"GLYNASE PresTab\u00ae (glyburide) Tablets (1.5 mg, 3 mg, and 6 mg)","year":"2023"},{"key":"10.1016\/j.ejmech.2026.119009_bib372","series-title":"Dia\u03b2eta\u00ae (glyburide) Tablets USP (1.25 mg, 2.5 mg, 5 mg)","year":"2016"},{"key":"10.1016\/j.ejmech.2026.119009_bib373","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.2337\/dc17-0595","article-title":"Pharmacologic differences of sulfonylureas and the risk of adverse cardiovascular and hypoglycemic events","volume":"40","author":"Douros","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib374","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.90.2.700","article-title":"Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker","volume":"90","author":"Tomai","year":"1994","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2026.119009_bib375","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejphar.2005.04.002","article-title":"The effect of gliclazide and glibenclamide on preconditioning of the human myocardium","volume":"515","author":"Loubani","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib376","series-title":"DIABINESE\u00ae (chlorpropamide) Tablets","year":"2009"},{"key":"10.1016\/j.ejmech.2026.119009_bib377","first-page":"1487","article-title":"Drug dosing adjustments in patients with chronic kidney disease","volume":"75","author":"Munar","year":"2007","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.ejmech.2026.119009_bib378","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00125-003-1143-3","article-title":"Sulphonylurea action revisited: the post-cloning era","volume":"46","author":"Gribble","year":"2003","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.119009_bib379","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2125.2005.02364.x","article-title":"Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism","volume":"59","author":"Shon","year":"2005","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib380","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/molecules25081937","article-title":"Metabolic-hydroxy and carboxy functionalization of alkyl moieties in drug molecules: prediction of structure influence and pharmacologic activity","volume":"25","author":"El-Haj","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119009_bib383","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/sj.bjp.0704062","article-title":"Glimepiride block of cloned beta-cell, cardiac and smooth muscle K(ATP) channels","volume":"133","author":"Song","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib384","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1053\/euhj.1998.1242","article-title":"Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide","volume":"20","author":"Klepzig","year":"1999","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ejmech.2026.119009_bib385","doi-asserted-by":"crossref","first-page":"3111","DOI":"10.1161\/01.CIR.103.25.3111","article-title":"Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide","volume":"103","author":"Mocanu","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.ejmech.2026.119009_bib353","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial","volume":"322","author":"Rosenstock","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.119009_bib386","series-title":"GLUCOTROL\u00ae (glipizide) Tablets","year":"2010"},{"key":"10.1016\/j.ejmech.2026.119009_bib387","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/j.1463-1326.2011.01496.x","article-title":"Variations in tissue selectivity amongst insulin secretagogues: a systematic review","volume":"14","author":"Abdelmoneim","year":"2012","journal-title":"Diabetes Obes. Metabol."},{"key":"10.1016\/j.ejmech.2026.119009_bib390","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10557-005-4970-2","article-title":"The sulfonylurea glipizide does not inhibit ischemic preconditioning in anesthetized rabbits","volume":"19","author":"Flynn","year":"2005","journal-title":"Cardiovasc. Drug Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib393","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1007\/s001250051236","article-title":"Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide","volume":"42","author":"Gribble","year":"1999","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.119009_bib394","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1007\/s001250100595","article-title":"Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells","volume":"44","author":"Lawrence","year":"2001","journal-title":"Diabetologia"},{"key":"10.1016\/j.ejmech.2026.119009_bib396","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1038\/sj.bjp.0703423","article-title":"On the mechanism of ADP-induced alteration of sulphonylurea sensitivity in cardiac ATP-sensitive K(+) channels","volume":"130","author":"Miyamura","year":"2000","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib397","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib354","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib355","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.2337\/dc08-1171","article-title":"Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis","volume":"31","author":"Bodmer","year":"2008","journal-title":"Diabetes Care"},{"key":"10.1016\/j.ejmech.2026.119009_bib356","first-page":"1220","article-title":"Profound hypoglycemia with the addition of a tricyclic antidepressant to maintenance sulfonylurea therapy","volume":"144","author":"True","year":"1987","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ejmech.2026.119009_bib357","doi-asserted-by":"crossref","first-page":"195","DOI":"10.2190\/PM.46.2.f","article-title":"A case report on escitalopram-induced hyperglycaemia in a diabetic patient","volume":"46","author":"Zuccoli","year":"2013","journal-title":"Int. J. Psychiatr. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib358","first-page":"12","article-title":"Hypoglycemia associated with high doses of sertraline and sulphonylurea compound in a noninsulin-dependent diabetes mellitus patient","volume":"6","author":"Takhar","year":"1999","journal-title":"Can. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib359","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000446497","article-title":"A rare reason of hyperinsulinism: Munchausen syndrome by proxy","volume":"86","author":"Ak\u0131n","year":"2016","journal-title":"Horm. Res. Paediatr."},{"key":"10.1016\/j.ejmech.2026.119009_bib360","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/FTD.0b013e318197b7d7","article-title":"Hypoglycemia in a healthy toddler","volume":"31","author":"Glatstein","year":"2009","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejmech.2026.119009_bib361","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1136\/adc.82.5.392","article-title":"Deliberate sulphonylurea poisoning mimicking hyperinsulinaemia of infancy","volume":"82","author":"Owen","year":"2000","journal-title":"Arch. Dis. Child."},{"key":"10.1016\/j.ejmech.2026.119009_bib362","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2017-220044","article-title":"Dilemma of diagnosing sulphonylurea overdose in children: deliberations and considerations before reaching a diagnosis","volume":"2017","author":"Gopal-Kothandapani","year":"2017","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib363","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1515\/jpem-2001-0814","article-title":"Gliclazide-induced hepatitis, hemiplegia and dysphasia in a suicide attempt","volume":"14","author":"Caksen","year":"2001","journal-title":"J. Pediatr. Endocrinol. Metab."},{"key":"10.1016\/j.ejmech.2026.119009_bib364","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1258\/rsmmsl.46.3.263","article-title":"Suicide by combined insulin and glipizide overdose in a non-insulin dependent diabetes mellitus physician: a case report","volume":"46","author":"Rao","year":"2006","journal-title":"Med. Sci. Law"},{"key":"10.1016\/j.ejmech.2026.119009_bib365","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0361-1124(79)80062-3","article-title":"Suicidal overdoses with hypoglycemic agents","volume":"8","author":"Bobzien","year":"1979","journal-title":"JACEP"},{"issue":"Suppl. 1","key":"10.1016\/j.ejmech.2026.119009_bib398","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0026-0495(00)80079-7","article-title":"Gliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study","volume":"49","author":"Noda","year":"2000","journal-title":"Metabolism"},{"key":"10.1016\/j.ejmech.2026.119009_bib399","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/0922-4106(91)90069-T","article-title":"Gliclazide: a general free radical scavenger","volume":"208","author":"Scott","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib400","doi-asserted-by":"crossref","first-page":"8854","DOI":"10.18632\/oncotarget.12673","article-title":"Improving anticancer drug development begins with cell culture: misinformation perpetrated by the misuse of cytotoxicity assays","volume":"8","author":"Eastman","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119009_bib401","article-title":"Excessive concentrations of kinase inhibitors in translational studies impede effective drug repurposing","volume":"4","author":"Liu","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib402","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197634","article-title":"Binding of sulphonylureas to plasma proteins \u2013 a KATP channel perspective","volume":"13","author":"Proks","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119009_bib403","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s002800051011","article-title":"Effects of protein binding on the in vitro activity of antitumour acridine derivatives and related anticancer drugs","volume":"45","author":"Finlay","year":"2000","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib404","first-page":"3248","article-title":"Unpredicted clinical pharmacology of UCN-01 caused by specific binding to human alpha1-acid glycoprotein","volume":"58","author":"Fuse","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib405","article-title":"A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer","volume":"13","author":"Schweizer","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119009_bib406","doi-asserted-by":"crossref","first-page":"6377","DOI":"10.1038\/s41598-021-85969-x","article-title":"Phase Ib trial of reformulated niclosamide with abiraterone\/prednisone in men with castration-resistant prostate cancer","volume":"11","author":"Parikh","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119009_bib407","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.2022.6147","article-title":"Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer: the MA.32 randomized clinical trial","volume":"327","author":"Goodwin","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ejmech.2026.119009_bib408","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3390\/ph17030396","article-title":"Metformin and breast cancer: current findings and future perspectives from preclinical and clinical studies","volume":"17","author":"Corleto","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119009_bib409","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1158\/1078-0432.CCR-20-1967","article-title":"Statins as anticancer agents in the era of precision medicine","volume":"26","author":"Longo","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119009_bib410","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3390\/jcm8060819","article-title":"Effect of statin on cancer incidence: an umbrella review of meta-analyses","volume":"8","author":"Jeong","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib411","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1056\/NEJM199605023341802","article-title":"Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease","volume":"334","author":"Omenn","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib412","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1056\/NEJM199404143301501","article-title":"The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers","volume":"330","year":"1994","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2026.119009_bib414","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1670845","article-title":"Overcoming barriers to off-patent drug repurposing: a lifecycle-based policy solutions","volume":"16","author":"Garcia-Diaz","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib415","volume":"2014","author":"Roin","year":"2014"},{"key":"10.1016\/j.ejmech.2026.119009_bib416","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104390","article-title":"UCL Repurposing TIN Committee, Therapeutic innovation in drug repurposing: challenges and opportunities","volume":"30","author":"Recino","year":"2025","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2026.119009_bib417","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3389\/fphar.2019.01664","article-title":"On-label or off-label? Overcoming regulatory and financial barriers to bring repurposed medicines to cancer patients","volume":"10","author":"Verbaanderd","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib418","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1017\/jme.2024.171","article-title":"A regulatory roadmap for repurposing: comparing pathways for making repurposed drugs available in the EU, UK, and US","volume":"52","author":"Scholte","year":"2024","journal-title":"J. Law Med. Ethics"},{"key":"10.1016\/j.ejmech.2026.119009_bib419","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3389\/fonc.2017.00273","article-title":"Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics","volume":"7","author":"Hernandez","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119009_bib420","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nrd.2018.92","article-title":"Overcoming the legal and regulatory barriers to drug repurposing","volume":"18","author":"Breckenridge","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119009_bib421","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1419772","article-title":"Pathways for non-manufacturers to drive generic drug repurposing for cancer in the U.S","volume":"15","author":"Crittenden","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119009_bib423","series-title":"Regulatory Actions to Advance Generic Drug Repurposing","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119009_bib424","doi-asserted-by":"crossref","DOI":"10.1177\/11795514221074663","article-title":"Position of sulfonylureas in the current era: review of national and international guidelines,","volume":"15","author":"Mohan","year":"2022","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"key":"10.1016\/j.ejmech.2026.119009_bib426","doi-asserted-by":"crossref","first-page":"3869","DOI":"10.3390\/molecules26133869","article-title":"How does glycation affect binding parameters of the albumin-gliclazide system in the presence of drugs commonly used in diabetes? In vitro spectroscopic study","volume":"26","author":"Wiglusz","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119009_bib428","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.119009_bib429","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.apsb.2021.09.006","article-title":"Repurposing non-oncology small-molecule drugs to improve cancer therapy: current situation and future directions","volume":"12","author":"Fu","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119009_bib430","first-page":"1369","article-title":"METNET: a phase II trial of metformin in patients with well-differentiated neuroendocrine tumours","volume":"16","author":"Glasberg","year":"2022","journal-title":"ecancermedicalscience"},{"key":"10.1016\/j.ejmech.2026.119009_bib431","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2026.119009_bib432","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119009_bib433","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.122052","article-title":"Recent advances in the determination of unbound concentration and plasma protein binding of drugs: analytical methods","volume":"225","author":"Seyfinejad","year":"2021","journal-title":"Talanta"},{"key":"10.1016\/j.ejmech.2026.119009_bib434","article-title":"Enhanced in vitro release and permeability of glibenclamide by proliposomes: development, characterization and histopathological evaluation","volume":"63","author":"Khan","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2026.119009_bib435","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2016.02.012","article-title":"Development of solid lipid nanoparticles as carriers for improving oral bioavailability of glibenclamide","volume":"102","author":"Gon\u00e7alves","year":"2016","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejmech.2026.119009_bib436","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jddst.2017.02.001","article-title":"Enhancing bioavailability and controlling the release of glibenclamide from optimized solid lipid nanoparticles","volume":"38","author":"Elbahwy","year":"2017","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejmech.2026.119009_bib437","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.2147\/IJN.S139450","article-title":"CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties","volume":"14","author":"Mayer","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119009_bib438","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3390\/colloids8040042","article-title":"Co-encapsulation of paclitaxel and doxorubicin in liposomes layer by layer","volume":"8","author":"Mota D\u00edaz","year":"2024","journal-title":"Colloids Interfaces"},{"key":"10.1016\/j.ejmech.2026.119009_bib439","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3390\/pharmaceutics15020369","article-title":"Co-encapsulation of simvastatin and doxorubicin into pH-sensitive liposomes enhances antitumoral activity in breast cancer cell lines","volume":"15","author":"Duarte","year":"2023","journal-title":"Pharmaceutics"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600454X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342600454X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T08:11:24Z","timestamp":1787040684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342600454X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":413,"alternative-id":["S022352342600454X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119009","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sulfonylureas beyond diabetes: A comprehensive review on anticancer and off-target effects (1956\u20132025)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119009"}}